« Return to News | CROs/Service Providers

Quintiles Expands Phase I Capacity in London

Thursday, March 11, 2010 07:38 AM

Quintiles expanded its London-based phase I facility by 35 beds, bringing the total number of phase I beds in London to 105 and globally to 385. The CRO said this number will increase even further later this year as a result of the planned opening of a phase I unit in Hyderabad, India. That facility will initially have 50 beds with capacity for 100.

The larger London facility is adjacent to one of only five Biomedical Research Centres (BRCs) in the UK. BRC designation and associated funding is awarded by the government to encourage innovation and translational research in biomedicine. Quintiles said it will work closely with the BRC as appropriate.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.